Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
OS Therapies Incorporated is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. The company operates within the oncology and biotechnology industries, with a specific emphasis on cancer immunotherapy addressing indications with significant unmet medical need.
The company’s primary value driver is its lead immunotherapy program OST-HER2, which targets HER2-expressing osteosarcoma. OS Therapies positions itself as a focused developer in a niche oncology market, seeking regulatory pathways that include orphan drug designations and expedited approval mechanisms. The company was formed to advance late-stage assets acquired or licensed from prior developers and has evolved into a single-focus oncology company centered on osteosarcoma. Its shares trade publicly under the ticker OSTX following its transition to a public company.
Business Operations
OS Therapies operates primarily as a development-stage company without commercialized products, generating no material product revenue as of the most recent public disclosures. Its operations are centered on advancing OST-HER2, an immunotherapy candidate designed to stimulate an immune response against HER2-expressing tumor cells in osteosarcoma patients. Clinical development activities, regulatory engagement, and manufacturing oversight represent the company’s core operational functions.
The company’s activities are largely conducted through outsourced clinical research organizations and manufacturing partners, a common model for early-stage biotechnology firms. OS Therapies does not report diversified operating segments; instead, its business is managed as a single reporting unit focused on oncology drug development. Data on material subsidiaries or joint ventures is inconclusive based on available public sources.
Strategic Position & Investments
Strategically, OS Therapies is focused on advancing its lead candidate through late-stage clinical development with the goal of regulatory approval in the United States. Growth initiatives center on completing clinical trials for OST-HER2, pursuing regulatory designations that may accelerate review, and evaluating lifecycle expansion opportunities within osteosarcoma and potentially other HER2-expressing cancers.
The company’s core asset, OST-HER2, was acquired or licensed from Advaxis, Inc., providing OS Therapies with an established clinical data foundation. Beyond this asset, the company has disclosed limited information regarding additional pipeline programs, acquisitions, or equity investments. Any expansion into additional oncology indications or technologies has not been conclusively verified in public filings.
Geographic Footprint
OS Therapies is headquartered in the United States and conducts the majority of its corporate, regulatory, and development activities domestically. Its clinical trial activities include sites within North America, reflecting its initial regulatory focus on the U.S. market.
International operations are limited and primarily related to clinical research participation and regulatory considerations. The company does not report significant physical infrastructure or commercial operations outside the United States, and its global presence remains development-oriented rather than commercial in nature.
Leadership & Governance
OS Therapies is led by an executive team with experience in biotechnology and pharmaceutical development, particularly in oncology-focused organizations. The leadership emphasizes capital efficiency, regulatory discipline, and targeted development in rare cancers with high unmet need.
Key executives include:
- Paul Romness – Chief Executive Officer
- Michael Devlin – President
- Robert P. Donnelly – Chief Financial Officer
Information regarding founders and additional board members is limited in publicly available sources, and certain details of governance structure are inconclusive based on available public disclosures.